FOR IMMEDIATE RELEASE
Contact:Emily GrandahlMarketing Coordinator, MitoActionemily@mitoaction.org(888) …
Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY™ (elamipretide HCl), the First Therapy for Progressive and Life-limiting Ultra-rare Genetic Disease Barth Syndrome
“The approval of FORZINITY, the first treatment option for Barth syndrome and the first approved mitochondria-targeted …
BPGbio Sponsors MitoAction Energy Walk at Boston’s Franklin Park Zoo on September 27th, 2025
Company honored in its commitment to patients and families living with mitochondrial disease; invites the community to …
FDA denies approval for dichloroacetate (DCA), a treatment for Pyruvate Dehydrogenase Complex Deficiency (PDCD).
Earlier today, Saol Therapeutics shared the U.S. Food and Drug Administration (FDA) has issued a Complete Response …
